Michael Li, MD, MPH

Transplant hepatologist @UCSF studying cancer and autoimmune liver disease | @UCSFTransplant @BrighamGI @HarvardChanSPH @IcahnMountSinai @BrownUniversity alum

[Michael Li, MD, MPH @MichaelLiMD]

For anyone attending #NCCN2025 in Orlando, I'm excited to be speaking during the immune checkpoint inhibitor toxicities session tomorrow (Friday 3/28). Looking forward to talking about immune-mediated hepatitis with an oncology audience!

@NCCN @UCSFCancer #livertwitter

[Journal of Hepatology @JHepatology]

🆕EASL Clinical Practice Guidelines on the management of #hepatocellularcarcinoma❗️

✅Updated advice for managing patients with #HCC & comprehensive review of pertinent data

Full text👉https://t.co/IAMvBDv0CT

#CPGs
#LiverTwitter
@EASLnews
@EASLedu
@AleksanderKrag

[ACG @AmCollegeGastro]

Apply for the #ACGInstitute Clinical Research Leadership Program!

Learn research leadership skills to maintain a successful independent research program. For US physician members 2-15 years post-fellowship.

Apply by November 15
➡️ https://t.co/SsGxdcMyro
#CRLP @NeenaSAbrahamMD

[Journal of Hepatology @JHepatology]

Immunotherapy for hepatocellular carcinoma

➡️The next evolution in expanding access to liver transplantation

Full text here👉https://t.co/2Uj9hYWhA0

@MichaelLiMD
@SherrieBhoori
#LiverTwitter

[CGH @AGA_CGH]

@MichaelLiMD et al found that outcomes of high-grade immune checkpoint inhibitor hepatitis were similar in hospitalized and non-hospitalized patients, suggesting that not all patients with high ALT levels need to be hospitalized https://t.co/pLmo4abVYZ

[Michael Li, MD, MPH @MichaelLiMD]

Check out our review of immunotherapy in HCC with a focus on its role in expanding access to curative liver transplantation, now out in @JHepatology. It was amazing working with Vincenzo Mazzaferro and Neil Mehta in this joint San Francisco-Milan effort!

https://t.co/z8CuZEKUvT

[Elliot Tapper @ebtapper]

Patients want to be in clinical trials but are rarely asked

And - key point - if your trial seeks to help them FEEL better, they really want to be asked

This study in @HepCommJournal from @MichaelLiMD is about PSC but the message is universal

https://t.co/Jhz4ghCkWG

[Michael Li, MD, MPH @MichaelLiMD]

Congrats @MelindaBWangMD! So happy that you’re staying, looking forward to working with you as a fellow!

[UCSF Gastroenterology Fellowship @UCSFGIfellows]

We are so excited to announce our incoming all-star ✨cohort of GI Fellows starting in 2024! We are so lucky to have them 🥰 & cannot wait to work with them! @priyakathpalia @SaraLewinMD

[Melinda Wang @MelindaBWangMD]

Incredibly honoured to attend #TLM23 as an Emerging Liver Scholar! Thank you so much @ggarciatsao and @AASLDFoundation for the opportunity and for those who welcomed me to the community!

🌟struck and inspired to help improve liver related care! @AASLDtweets #LiverTwitter

[AASLD Foundation @AASLDFoundation]

Research by @MelindaBWangMD emphasizes the complexity of symptoms PSC patients experience & highlights the importance of considering these symptoms in clinical trials and future research. Learn more about why this research received a 2023 Abstract Award at https://t.co/5EETY09WoK

[Jin Ge @egnij]

🆕Now on Preprint: https://t.co/XOPoYFIQZB

Our study comparing the @UCSF secure implementation of @OpenAI gpt-35-turbo #LLM model versus manual chart review for extraction of distinct data elements from #HCC imaging reports

[Michael Li, MD, MPH @MichaelLiMD]

Key points:
⭐️ Early GI/hepatology consultation was associated with faster liver enzyme normalization in patients with steroid-refractory ICI hepatitis
⭐️ A mediation analysis showed that this beneficial effect was driven by earlier initiation of additional immunosuppression

[Michael Li, MD, MPH @MichaelLiMD]

Hey #livertwitter, if you'd like some validation for our amazing specialty, check out our study in @JNCCN showing the benefits of early GI/liver consultation in immune checkpoint inhibitor hepatitis: https://t.co/ZHM70aBGLr

@AlexSVogel @JordanSackMD @UCSFTransplant @BrighamGI

[Melinda Wang @MelindaBWangMD]

Super excited to share our work developing the TeLeFI (Tele-Liver Frailty Index) to measure frailty in patients with cirrhosis via telemedicine!

https://t.co/FOMEEEtvly

[Bilal Hameed @BilalUCSF]

From the newest members of our amazing group to the leaders at the top, my work family inspires greatness.
⁦@JessBRubin⁩ ⁦@JoeCullaro⁩ ⁦@egnij⁩ ⁦@MonikaSarkarMD⁩ ⁦@MichaelLiMD⁩ ⁦@UCSFLiverCenter⁩ ⁦@UCSFTransplant⁩

[AASLD @AASLDtweets]

This #WomensHistoryMonth, we're honored to highlight @MonikaSarkarMD, NIH-funded researcher in women's reproductive health and NAFLD and Chair, AASLD Women's Initiatives Committee. #LiverTwitter #WHM
@norahterrault

[Michael Li, MD, MPH @MichaelLiMD]

@ebtapper @doctornikkid Jen Lai loves recommending Greek yogurt with nuts as a late night snack since you get protein without a lot of sodium and patients can order it from the hospital menu. I heard that suggestion so many times on rounds that I’m slightly worried she’s in the pocket of Big Yogurt.

[Michael Li, MD, MPH @MichaelLiMD]

Huge congrats to UCSF IM resident and (hopefully) future hepatologist @MelindaBWangMD for receiving an @AmCollegeGastro Medical Resident Research Award to study the effects of Stelara in PSC. So excited to work with you on this study and many more!

#livertwitter @UCSFIMChiefs

[Michael Li, MD, MPH @MichaelLiMD]

@matownsend @BrighamGI Thanks Matt! Hope we can catch up at a GI meeting soon.

[Michael Li, MD, MPH @MichaelLiMD]

I'm so honored to receive an @AmCollegeGastro Junior Faculty Development Award to study outcomes of HCC immunotherapy! Many thanks to my amazing co-mentors Jen Lai and Larry Fong and my @UCSFTransplant and @UCSFCancer collaborators for their support.
#ACGInstitute #livertwitter

[ACG @AmCollegeGastro]

Congratulations, Michael Li, MD, MPH, on your ACG Junior Faculty Development Award!
#ACGInstitute #FutureofGI #GITwitter

➡️ https://t.co/VdlNjluIuu